Echinocandins in the management of invasive fungal infections, part 1 (Q28262565)

invasive fungal infections

Europe PubMed Central

title

Echinocandins in the management of invasive fungal infections, part 1 (English)

0 references

main subject

1 reference

Michele I Morris

1

0 references

Mark Villmann

series ordinal

2

0 references

language of work or name

English

0 references

publication date

15 September 2006

0 references

published in

American Journal of Health-System Pharmacy

0 references

volume

63

0 references

issue

18

0 references

page(s)

1693-703

0 references

cites work

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Changing face of health-care associated fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Clinical efficacy of echinocandin antifungals

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Antibiotics that inhibit fungal cell wall development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Echinocandin antifungal drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Antifungal agents: mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Echinocandins: role in antifungal therapy, 2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

In vitro activity of anidulafungin against selected clinically important mold isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Pharmacokinetics/pharmacodynamics of echinocandins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Anidulafungin: a new echinocandin with a novel profile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A successful treatment with micafungin of candidemia due to Candida krusei

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Successful treatment with micafungin in a case of candidemia associated with pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

The natural history of esophageal candidiasis after successful treatment in patients with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Caspofungin: the first in a new class of antifungal agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Anidulafungin: an echinocandin antifungal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P1